Inventiva's Promising Phase 2 Results for Lanifibranor with Empagliflozin
Inventiva Showcases Breakthrough Phase 2 Trial Results
Inventiva, a clinical-stage biopharmaceutical company, is making headlines with its recent announcement regarding the Phase 2 LEGEND trial results of lanifibranor in combination with empagliflozin. These results are set to be presented at an upcoming prestigious liver health meeting. This exciting development underscores the company's commitment to finding effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) and Type-2 Diabetes (T2D).
Details of the Upcoming Presentation
The celebration of scientific achievement will take place during the 75th Annual American Association for the Study of Liver Diseases (AASLD) meeting. This event is scheduled from November 15 to 19, providing a platform for medical professionals to engage with innovative research.
Abstract Title and Presentation Highlights
The abstract titled "Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D)" has been selected as a late breaker presentation. This recognition highlights the importance and timeliness of the findings, reflecting on significant advances in treating these challenging health conditions.
The Science Behind Lanifibranor
Lanifibranor, Inventiva's frontrunner product candidate, is an orally-administered small molecule that showcases remarkable potential in inducing antifibrotic and anti-inflammatory responses. By activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, lanifibranor enhances beneficial metabolic changes in the body. Unlike its competitors that target fewer PPAR isoforms, lanifibranor is unique as it is the only pan-PPAR agonist in clinical trials for MASH/NASH.
Clinical Insights and Regulatory Milestones
Lanifibranor's well-balanced activation of PPAR?, PPAR?, and partial activation of PPAR? has resulted in a favorable tolerability profile noted in both clinical and preclinical studies. The FDA has granted it Fast Track and Breakthrough Therapy designations, further underscoring its potential significance in the treatment landscape for MASH/NASH.
About Inventiva's Strategic Focus
This French biopharmaceutical company is dedicated to developing innovative therapies that meet critical gaps in patient care, specifically targeting metabolic diseases. Currently, Inventiva is advancing lanifibranor through necessary phases while also maintaining a robust preclinical pipeline including drug candidates aimed at addressing a variety of medical needs.
Current and Future Clinical Trials
Inventiva's continued commitment to addressing metabolic diseases is exemplified by its pivotal Phase III clinical trial, NATiV3, which also focuses on adult patients suffering from MASH/NASH. With a well-rounded pipeline, including odiparcil for MPS VI treatment, Inventiva is strategically reviewing its clinical focuses to maximize development potential.
Contact Information for Inquiries
Inventiva is strong on communication, ensuring that stakeholders stay informed and engaged. Pascaline Clerc, PhD, the EVP of Strategy and Corporate Affairs, is reachable for press inquiries. Additional contact points are available for broader investor relations, ensuring transparency and accessibility for those interested in the company's future.
Frequently Asked Questions
What is the significance of the LEGEND trial results?
The LEGEND trial results signify a potential breakthrough in treating MASH and T2D, emphasizing the effectiveness of lanifibranor when combined with empagliflozin.
What are the key findings from the Phase 2 trial?
The key findings suggest that the combination therapy could lead to metabolic improvements for patients suffering from MASH and T2D.
Who are the authors presenting the study?
The study will be presented by a team of experts including Michelle Lai, Onno Holleboom, and others who contributed significantly to this clinical research.
What is the mechanism of action for lanifibranor?
Lanifibranor works by activating all three PPAR isoforms, helping to manage inflammation, fibrosis, and metabolic regulation in patients.
How can I get in touch with Inventiva for more information?
You can contact Pascaline Clerc at Inventiva via email for press inquiries or general questions about the ongoing trials and developments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Revolutionizing Forex Trading with FinTech360’s Communication Hub
- Nokia Corporation's Strategic Share Buyback Update for Investors
- Comstock Secures Prestigious ENERGY STAR Certification in 2024
- Hightower's Strategic Move: Acquiring NEPC for Growth
- Lucid's Strategic Stock Sale Ensures Financial Stability Until 2026
- Lumen Technologies Partners with Meta: A New Era in AI Services
- Earnings Insights: Quest Diagnostics Performance Summary
- Whistle Express Car Wash Launches Discounts for AAA Members
- Sify Technologies Sets Stage for Earnings Report with Insights
- Verizon's Upcoming Q3 Earnings: A Promising Return for Telecom
Recent Articles
- ECD Automotive Design Set to Shine at Upcoming Investor Conference
- NEO Battery Materials Ventures Into Solar Recycling with Lotus
- Jennifer C. Lewis Takes Lead as CDM Smith's New Director
- StemSation International Pursues Acquisition of Marketing Firm
- Ensign Group Welcomes Mark Parkinson to Its Board of Directors
- Veru Inc. Showcases Enobosarm's Impact on Weight Loss
- Join CFC's Investor Conference Call for Q1 Insights
- ZETWERK's Major Solar Module Order Highlights Market Growth
- Zeta Global's Strategic Move: Acquiring LiveIntent for Growth
- CSW Industrials Prepares for Upcoming Earnings Call Event
- First Trust Introduces Exciting New ETFs to Boost Growth
- Oconee Federal Financial Corp. Reports Impressive Quarterly Gains
- Victor Lee Joins VCI Global as Executive Director to Drive Growth
- Surge of Residual Market Policies Reflects Growing Weather Risks
- Growth Insights and Trends in the Industrial Sensors Market
- Mastercard Revolutionizes Cross-Border Payment Solutions Today
- SchooLinks Secures $80 Million Funding to Enhance CCR Solutions
- Anello Photonics Partners with Space Force to Enhance Defense
- Morgan Stanley Surveys 401(k) Plan Trends and Best Practices
- Exploring Recent Changes in Medical Marijuana Access Worldwide
- Wolters Kluwer's Enablon ESG Excellence Receives 2024 Award
- WEBTOON Investors Can Seek Justice with Schall Law Firm
- Discover ENVO UPT: Your Versatile Electric Mobility Solution
- Catalent's CEO Confirms Leadership Post Novo Holdings Acquisition
- Investors Seek Justice in Metagenomi, Inc. Class Action Lawsuit
- PM Modi Envisions India's Future in 6G and Ethical AI Driving Innovation
- Legal Action Alert: iLearningEngines, Inc. Investors Unite
- XTI Aerospace Launches Invigorating Podcast on Aviation Trends
- Northvolt Advances in Securing a Crucial Financing Package
- Craig Tyler Takes the Helm as Grasons' New Brand Leader
- Cerillion Reports Impressive Growth and Year-End Outlook for 2024
- Unanet Achieves High User Satisfaction with Q3 Success
- Ocean Wilsons to Sell Major Stake to MSC for Over R$4 Billion
- Datasea Secures $4 Million Financing to Advance Technology
- Elite Athletes Invest in LEAD's Innovative Locker Room Fund
- Midwich Group Revises Revenue Forecasts Amid Market Challenges
- Co-Diagnostics, Inc. Showcases Innovations at Medlab Africa 2024
- Financial Triumph: Skytale Advises Swan Center Expansion
- Rayonier Declares 4th Quarter Dividend and Company Outlook
- Deliberately.ai Launches Revolutionary AI Legal Platform
- Pineapple Energy Expands Solar Initiatives with New Contracts
- Smartpress Captivates Audiences at the Adobe MAX Event
- Ecopetrol S.A. Seals Successful Cash Tender Offer for Notes
- TriNet's Leadership Update: Varsha Kakati Takes Charge
- O Positiv TV Ad Launch: Elevating Women's Health Awareness
- Zeta Global's Strategic Acquisition of LiveIntent Enhances Growth
- Nurix's NX-5948 Shows Promise for Relapsed WM with Buy Rating
- Sempra Energy: Navigating Regulatory Changes with Resilience
- BMO Keeps Positive Outlook on Structure Therapeutics Stock
- Citi Sees Bright Future for BKV Corp, Initiates Buy Rating